Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Expect AZ To Hike Byetta's Price Ahead Of Teva's Generic

Executive Summary

AstraZeneca PLC entered into a patent litigation settlement with Teva, giving the latter company the OK to market a generic version of Byetta (exenatide), a glucagon-like peptide-1 receptor agonist approved in the US to treat type 2 diabetes, beginning in October 2017. But before then, AstraZeneca is likely to hike Byetta's price – possible a few times.


Related Content

Express Scripts Diabetes Program Caps Drug Costs, Targets Adherence
Drug Price Competition: An 'Eye-Of-The-Beholder' Debate
Lilly's Trulicity OK'd; can it top GLP-1 market?
Amylin's Bydureon endures rejection; finally embraced by FDA


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts